Literature DB >> 1727486

Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes.

R L Willey1, F Maldarelli, M A Martin, K Strebel.   

Abstract

Intracellular transport and processing of the human immunodeficiency virus type 1 (HIV-1) envelope precursor glycoprotein, gp160, proceeds via the endoplasmic reticulum and Golgi complex and involves proteolytic processing of gp160 into the mature virion components, gp120 and gp41. We found that coexpression of gp160 and human CD4 in HeLa cells severely impaired gp120 production due to the formation of intracellular gp160-CD4 complexes. This CD4-mediated inhibition of gp160 processing was alleviated by coexpression of the HIV-1-encoded Vpu protein. The coexpression of Vpu and CD4 in the presence of gp160 resulted in increased degradation of CD4. Although the precise mechanism(s) responsible for the Vpu effect is presently unclear, our findings suggest that Vpu may destabilize intracellular gp160-CD4 complexes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727486      PMCID: PMC238279     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

Authors:  T Klimkait; K Strebel; M D Hoggan; M A Martin; J M Orenstein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Intracellular processing of the gp160 HIV-1 envelope precursor. Endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex.

Authors:  B S Stein; E G Engleman
Journal:  J Biol Chem       Date:  1990-02-15       Impact factor: 5.157

3.  Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum.

Authors:  L Buonocore; J K Rose
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

4.  A novel gene of HIV-1, vpu, and its 16-kilodalton product.

Authors:  K Strebel; T Klimkait; M A Martin
Journal:  Science       Date:  1988-09-02       Impact factor: 47.728

Review 5.  HIV-2 link to AIDS in West Africa.

Authors:  I Romieu; R Marlink; P Kanki; S M'Boup; M Essex
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

6.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection.

Authors:  C M Gorman; G T Merlino; M C Willingham; I Pastan; B H Howard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

8.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  Downregulation of cell surface molecules during noncytopathic infection of T cells with human immunodeficiency virus.

Authors:  M Stevenson; X H Zhang; D J Volsky
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

10.  HIV requires multiple gp120 molecules for CD4-mediated infection.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; P L Nara
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

View more
  109 in total

1.  Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1.

Authors:  Che Ma; Francesca M Marassi; David H Jones; Suzana K Straus; Stephan Bour; Klaus Strebel; Ulrich Schubert; Myrta Oblatt-Montal; Mauricio Montal; Stanley J Opella
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Authors:  Raphaël Vigan; Stuart J D Neil
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

3.  C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif.

Authors:  Amy J Andrew; Sandra Kao; Klaus Strebel
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 4.  HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication.

Authors:  Alison L Greenway; Gavan Holloway; Dale A McPhee; Phoebe Ellis; Alyssa Cornall; Michael Lidman
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

Review 5.  Ion channels as antivirus targets.

Authors:  Xin Liang; Zhi-Yuan Li
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

Review 6.  Comparative NMR studies demonstrate profound differences between two viroporins: p7 of HCV and Vpu of HIV-1.

Authors:  Gabriel A Cook; Hua Zhang; Sang Ho Park; Yan Wang; Stanley J Opella
Journal:  Biochim Biophys Acta       Date:  2010-08-18

7.  The vpu protein of human immunodeficiency virus type 1 plays a protective role against virus-induced apoptosis in primary CD4(+) T lymphocytes.

Authors:  Satoshi Komoto; Shoutaro Tsuji; Madiha S Ibrahim; Yong-Gang Li; Jiranan Warachit; Koki Taniguchi; Kazuyoshi Ikuta
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1.

Authors:  T D Duensing; H Fang; D W Dorward; S H Pincus
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 9.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

10.  Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin.

Authors:  Y Morikawa; E Barsov; I Jones
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.